B&L finishes purchase of new fluoroquinolone

Article

Rochester, NY-Bausch & Lomb has completed the purchase of InSite Vision's ISV-403 compound for the treatment of ocular infections. Bausch & Lomb gave InSite Vision an undisclosed cash sum and reimbursement of certain product development expenses. In exchange, InSite Vision will give Bausch & Lomb a percentage of future product sales in all licensed countries.

Recent Videos
Vicki Chan, MD, shares pearls for leveraging the power of social media in health care
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
John Bladen, MBBS, BSc, MRCS, PGCert, PhD, FRCOphth, consultant ophthalmologist and oculoplastic surgeon, King's College Hospital NHS Foundation Trust, London, UK, speaks with Ophthalmology Times Europe's® Caroline Richards
rande, CFP, and John S. Grande, CFP, of Grande Financial Services, continue their discussion with Ophthalmology Times®' Sheryl Stevenson
What keeps you up at night?
S.K. Steven Houston III, MD, discusses retina innovations in use in his practice, including the NGENUITY 1.4 upgrade from Alcon
Related Content
Mental health and ophthalmology

Mental health and ophthalmology

Article
Commercial real estate and your practice, part two with Colin Carr

Commercial real estate and your practice, part two with Colin Carr

Podcast
Minimizing the carbon footprint of ophthalmic surgeries

Minimizing the carbon footprint of ophthalmic surgeries

Article
Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

Podcast
Advocacy in Ophthalmology

Advocacy in Ophthalmology

Article
One shingle at a time: Starting a solo practice

One shingle at a time: Starting a solo practice

Article
© 2024 MJH Life Sciences

All rights reserved.